Compound for the treatment of bacterial infections of various etiologies in humans

Abstract

The invention relates to a novel compound manufactured with the procedure of synthesis of bouncing Carvacrol and Lidocaine into one stable compound. Use of the compound as an active compound / potent antimicrobial for the treatment of bacterial infections in humans caused by pathogens resistant to antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus faecalis, Mycobacterium tuberculosis, Escherichia spp. E. coli, Salmonella spp. Pasteurella spp., Corynebacterium spp., Bacillus spp., Bacillus anthracis, Clostridium spp., Spherophorus spp., Candida spp., Trichophyton spp., Microsporum spp., Mycobacterium spp., Vibrio spp., Cryp-tosporidium spp., Microsporidia spp., Listeria monocytogenes, Lawsonia intracellu-laris, Treponema dysenteriae, Enterococcus spp., Haemophilus spp., Campylobacter spp., Chlamydia spp., Brucella spp., and other pathogenic bacterial species.